AUROPHARMA — Aurobindo Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Aurobindo Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	R2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	230,985	247,746	234,555	248,554	290,019
Cost of Revenue
Gross Profit	124,866	139,693	124,020	125,295	163,990
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	191,900	175,409	203,992	223,417	248,724
Operating Profit	39,085	72,337	30,563	25,136	41,295
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	37,430	73,436	33,727	26,125	43,800
Provision for Income Taxes
Net Income After Taxes	28,437	53,338	26,471	19,277	31,690
Minority Interest
Net Income Before Extraordinary Items
Net Income	28,451	53,348	26,482	19,275	31,730
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	28,451	53,348	26,482	19,275	31,730
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	49.4	57.9	47.4	33	56.5
Dividends per Share